Noncoding RNAs and hyperthermic intraperitoneal chemotherapy in advanced gastric cancer

Lisi Zeng; Quanxing Liao; Xiaohui Zeng; Jiacai Ye; Xianzi Yang; Siyu Zhu; Hongsheng Tang; Gaojie Liu; Weiwen Cui; Shaohua Ma; Shuzhong Cui

doi:10.1080/21655979.2021.2021348

Noncoding RNAs and hyperthermic intraperitoneal chemotherapy in advanced gastric cancer

Bioengineered. 2022 Feb;13(2):2623-2638. doi: 10.1080/21655979.2021.2021348.

Authors

Lisi Zeng¹, Quanxing Liao², Xiaohui Zeng¹, Jiacai Ye³, Xianzi Yang⁴, Siyu Zhu⁴, Hongsheng Tang², Gaojie Liu², Weiwen Cui⁵, Shaohua Ma^{6

7}, Shuzhong Cui^{2

8}

Affiliations

¹ Institute of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
² Department of the Second Area of Gastrointestinal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
³ Department of Radiotherapy, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
⁴ Department of Medical Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
⁵ Department of Bioengineering, University of California, Berkeley, California, USA.
⁶ Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
⁷ Tsinghua-Berkeley Shenzhen Institute (TBSI), Tsinghua University, Shenzhen, China.
⁸ State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.

Abstract

Gastric cancer (GC) is one of the most common malignant tumors globally. About 20-30% of patients with gastric cancer show peritoneal implantation metastasis at the first diagnosis. Peritoneal metastasis is responsible for 70% of deaths of patients with advanced gastric cancer. Although there are many ways to treat advanced gastric cancer, the prognosis of patients with recurrence is unsatisfactory. An auxiliary treatment with hyperthermic intraperitoneal chemotherapy (HIPEC), is an internationally recognized recommended treatment for advanced gastric cancer. A series of clinical trials have shown that HIPEC significantly improves the overall survival of patients with cancer. Compared with the cytoreductive surgery (CRS) alone, HIPEC combined with CRS markedly reduced the rate of peritoneal metastasis in patients with ovarian cancer and colorectal cancer. It has been demonstrated that HIPEC alters transcription of many genes by affecting non-coding RNAs, which may contribute to the suppressive effect of HIPEC on the synthesis of nucleic acids and proteins in cancer cells. This paper reviews the recent advances in understanding the role of non-coding RNAs in tumor invasion and metastasis of advanced gastric cancer. We also consider changes in noncoding RNA levels and other molecules in advanced gastric cancer cases treated with HIPEC. We hope that our review will provide a reference for future research on molecular epidemiology and etiology of advanced gastric cancer and promote precise treatment of this malignancy using HIPEC.

Keywords: Advanced gastric cancer; hyperthermic intraperitoneal chemotherapy (HIPEC); noncoding RNAs; prospects; research progress.

Publication types

Research Support, Non-U.S. Gov't
Video-Audio Media

MeSH terms

Cytoreduction Surgical Procedures*
Humans
Hyperthermic Intraperitoneal Chemotherapy*
RNA, Neoplasm* / metabolism
RNA, Untranslated* / genetics
RNA, Untranslated* / metabolism
Stomach Neoplasms* / genetics
Stomach Neoplasms* / metabolism
Stomach Neoplasms* / mortality
Stomach Neoplasms* / therapy
Survival Rate

Substances

RNA, Neoplasm
RNA, Untranslated

Grants and funding

This work was supported by the Natural Science Foundation of Guangdong Province under [Grant 2018A030310249, 2020A1515010818], National Natural Science Foundation of China under [Grant 81972918, 82172885], and Key Clinical Technique of Guangzhou under [Grant 2019ZD16].